Participated · Series A · May 2026

Waypoint Bio develops AI-driven design tools paired with an in‑house spatial pooled in vivo screening platform to create and validate CAR‑T and in vivo delivery vector designs aimed at solid tumors. The company combines computational exploration of complex design spaces with in vivo validation to learn which designs translate into meaningful effects on the tumor microenvironment. Waypoint plans to enter the clinic later this year with its first program and is using the new capital to run three CAR‑T trials in China. It is building out its platform to support additional in vivo CAR‑T targets and modalities. The company has attracted both new strategic investors and returning backers, indicating continued investor confidence as it advances clinical development.

Participated · Series A · Jun 2025

Ellipsis Health is a San Francisco, CA–based AI healthcare technology company that developed Sage, an emotionally intelligent AI voice agent for care management and behavioral health monitoring. Sage is powered by the company’s patented Empathy Engine and is designed to expand provider capacity, streamline workflows, and elevate patient engagement. The company serves leading healthcare providers and payers, focusing on patients with complex physical, behavioral, and social needs that drive the majority of healthcare costs. Ellipsis plans to use new funding to accelerate Sage adoption across healthcare providers, payers, and care management organizations, enhance its AI capabilities, and deepen integration with clinical systems. The company was founded and is led by CEO Mainul Mondal. Financially, Ellipsis has secured a $45M Series A to support these product and go-to-market initiatives. Ellipsis Health, based in San Francisco, develops an AI-powered speech-based vital sign to quantify and manage stress, depression, and anxiety at scale. Its integrated behavioral health solution uses machine-learning algorithms and cloud-based deep learning models to assess patient speech and generate automated assessments for clinical decision support. The company helps healthcare providers and payers identify and stratify patient populations. Ellipsis intends to use the new funding to grow its customer base, expand global partnerships, build a multidisciplinary team, and continue research and development of voice-based technology. It also plans to expand its voice vital sign to address the mental health of children and adolescents. Financially, the company raised a $26M Series A that brought total funding to $31M.

Participated · Seed · May 2025

Stately Bio is a biotechnology company building machine learning for regenerative medicine through a live-cell imaging platform. Its ML-driven imaging platform identifies and monitors cells in real time using label-free, live-cell compatible imaging without fluorescent tags or genetic modification. The technology quantifies diverse cell types, tracks differentiation progress, optimizes protocols, and can forecast manufacturing outcomes to accelerate process development and improve quality control for biopharma. On the discovery side, the company has applied the platform to improve differentiation of stem cells into mature cells, beginning with an industry-leading liver cell program. Its liver cells show 3x–10x improvement across a panel of metabolic assays of key liver functions versus the state of the art. Stately Bio plans to expand to additional cell types and is actively seeking partners for toxicity testing, disease modeling, and therapeutics. The company raised $12m in seed funding to scale its platform technology and mature its internal pipeline.

Participated · Series A · May 2024

Reunion Neuroscience is a clinical-stage biopharmaceutical company advancing RE104, a proprietary serotonergic psychedelic prodrug of 4‑OH‑DiPT. RE104 is designed as a fast-acting, short-duration therapy targeting the serotonin 2A receptor to deliver durable antidepressant effects while limiting in-clinic time to about half a day. In a Phase 1 study RE104 produced psychedelic effects similar in intensity and quality to psilocybin but lasting roughly 3–4 hours and demonstrated a favorable safety profile. The company expects to begin enrolling patients in the RECONNECT Phase 2 trial in postpartum depression, with results anticipated in Q2 2025, and is evaluating expansion into other indications including adjustment disorder in cancer. Reunion was acquired by MPM BioImpact in August 2023 and positions RE104 as the only 4‑OH‑DiPT prodrug in clinical development. The recent financing will support the RECONNECT trial and broader clinical advancement into psychiatric indications with high unmet need.

Participated · Seed · Apr 2024

Leash Biosciences applies artificial intelligence and machine learning to accelerate medicinal chemistry and the design of novel small-molecule therapeutics. The company combines ML with large chemical and biological datasets to predict protein-chemical interactions and rapidly generate candidate compounds. Leash reports it has physically generated over 17 billion high-quality protein-chemical interaction measurements to date. Headed by CEO Ian Quigley, the company is based in Salt Lake City, Utah and recently established new headquarters there. Leash plans to screen 500+ protein targets against many millions of machine learning-designed, proprietary chemicals by 2025. The recent financing will support development of a foundational machine learning model of medicinal chemistry intended to predict small-molecule drug candidates for any protein.